Note the A549 Lung Carcinoma chart and the 50 mg/kg that shows efficacy when compared to the control group. Also note that it is only one cycle of a drug that has cumulative effects in multiple cycles, i.e. the increased to 2 cycles of 200 mg/kg that shows increased efficacy over the same dose at one cycle.
Also, the computer model that is used to predict DLT and MTD as well as estimate anticipated efficacy levels are much more complex than a simple mouse to human conversion, which is mostly used to establish lowest starting dose for Phase 1 and 2 studies.
All in all, just using mouse model 50 mg/kg with a HED calculation 37 X 50 divided by 12.3 = 150.4 mg/m^2, not including other factors used in the computer conversion model.
Finally, interpolating the 50mg/kg curve against the control, HED calculation for efficacy against A549 most probably begins closer to 40 kg/mg than 50 mg/kg especially when considering low p21 biomarkers at 20 to 30 mg/kg, thus 40 X 37 divided by 12.3 = 120 mg/m^2 not including multiple cycle effect and other considerations in the computer efficacy model.
News 
Market Data 
Discover 
AI
